Cited In for PMID: 18836917

Year	Number of Results
2008	1
2009	2
2010	3
2011	6
2012	10
2013	13
2014	10
2015	13
2016	13
2017	17
2018	21
2019	29
2020	25
2021	33
2022	21
2023	14
2024	5

1

Infusion of the allogeneic cell line NK-92 in patients with advanced renal cell cancer or melanoma: a phase I trial.

Arai S, Meagher R, Swearingen M, Myint H, Rich E, Martinson J, Klingemann H. Arai S, et al. Cytotherapy. 2008;10(6):625-32. doi: 10.1080/14653240802301872. Cytotherapy. 2008. PMID: 18836917 Clinical Trial.

2

ISG12a promotes immunotherapy of HBV-associated hepatocellular carcinoma through blocking TRIM21/AKT/β-catenin/PD-L1 axis.

Deng R, Tian R, Li X, Xu Y, Li Y, Wang X, Li H, Wang L, Xu B, Yang D, Tang S, Xue B, Zuo C, Zhu H. Deng R, et al. iScience. 2024 Mar 19;27(4):109533. doi: 10.1016/j.isci.2024.109533. eCollection 2024 Apr 19. iScience. 2024. PMID: 38591006 Free PMC article.

3

Current Treatment Options for Renal Cell Carcinoma: Focus on Cell-Based Immunotherapy.

Hwang A, Mehra V, Chhetri J, Ali S, Tran M, Roddie C. Hwang A, et al. Cancers (Basel). 2024 Mar 19;16(6):1209. doi: 10.3390/cancers16061209. Cancers (Basel). 2024. PMID: 38539542 Free PMC article. Review.

4

Bulk RNA sequencing reveals the comprehensive genetic characteristics of human cord blood-derived natural killer cells.

Morimoto T, Nakazawa T, Maeoka R, Matsuda R, Nakamura M, Nishimura F, Yamada S, Nakagawa I, Park YS, Tsujimura T. Morimoto T, et al. Regen Ther. 2024 Feb 20;25:367-376. doi: 10.1016/j.reth.2024.02.002. eCollection 2024 Mar. Regen Ther. 2024. PMID: 38405180 Free PMC article.

5

Immunoengineering can overcome the glycocalyx armour of cancer cells.

Park S, Colville MJ, Paek JH, Shurer CR, Singh A, Secor EJ, Sailer CJ, Huang LT, Kuo JC, Goudge MC, Su J, Kim M, DeLisa MP, Neelamegham S, Lammerding J, Zipfel WR, Fischbach C, Reesink HL, Paszek MJ. Park S, et al. Nat Mater. 2024 Mar;23(3):429-438. doi: 10.1038/s41563-024-01808-0. Epub 2024 Feb 15. Nat Mater. 2024. PMID: 38361041

6

NK cells as powerful therapeutic tool in cancer immunotherapy.

Huang M, Liu Y, Yan Q, Peng M, Ge J, Mo Y, Wang Y, Wang F, Zeng Z, Li Y, Fan C, Xiong W. Huang M, et al. Cell Oncol (Dordr). 2024 Jan 3. doi: 10.1007/s13402-023-00909-3. Online ahead of print. Cell Oncol (Dordr). 2024. PMID: 38170381 Review.

7

CAR NK Cell Therapy for the Treatment of Metastatic Melanoma: Potential & Prospects.

Hibler W, Merlino G, Yu Y. Hibler W, et al. Cells. 2023 Nov 30;12(23):2750. doi: 10.3390/cells12232750. Cells. 2023. PMID: 38067178 Free PMC article. Review.

8

The nexus of natural killer cells and melanoma tumor microenvironment: crosstalk, chemotherapeutic potential, and innovative NK cell-based therapeutic strategies.

Rahimi A, Malakoutikhah Z, Rahimmanesh I, Ferns GA, Nedaeinia R, Ishaghi SMM, Dana N, Haghjooy Javanmard S. Rahimi A, et al. Cancer Cell Int. 2023 Dec 6;23(1):312. doi: 10.1186/s12935-023-03134-y. Cancer Cell Int. 2023. PMID: 38057843 Free PMC article. Review.

9

Recruiting In Vitro Transcribed mRNA against Cancer Immunotherapy: A Contemporary Appraisal of the Current Landscape.

Miliotou AN, Georgiou-Siafis SK, Ntenti C, Pappas IS, Papadopoulou LC. Miliotou AN, et al. Curr Issues Mol Biol. 2023 Nov 16;45(11):9181-9214. doi: 10.3390/cimb45110576. Curr Issues Mol Biol. 2023. PMID: 37998753 Free PMC article. Review.

10

NK cell subsets and dysfunction during viral infection: a new avenue for therapeutics?

Bjorgen JC, Dick JK, Cromarty R, Hart GT, Rhein J. Bjorgen JC, et al. Front Immunol. 2023 Oct 19;14:1267774. doi: 10.3389/fimmu.2023.1267774. eCollection 2023. Front Immunol. 2023. PMID: 37928543 Free PMC article. Review.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Results by year

Text availability

Article attribute

Article type

Publication date

212 results

Results by year